SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that the first patient was dosed in a Phase 1 pharmacokinetic clinical trial using Enhanze™ Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic. This biologic represents the third Roche proprietary compound directed to an exclusive target to enter the clinic as part of the Halozyme Roche collaboration. Initiation of the clinical trial has triggered a milestone payment under the agreement.
